Morgan Stanley’s AMAG Pharmaceuticals AMAG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-605,625
| Closed | -$5.69M | – | 7252 |
|
|
2020
Q3 | $5.69M | Buy |
605,625
+207,066
| +52% | +$1.97M | ﹤0.01% | 2590 |
|
|
2020
Q2 | $3.05M | Buy |
398,559
+307,695
| +339% | +$2.35M | ﹤0.01% | 3175 |
|
|
2020
Q1 | $560K | Sell |
90,864
-498,770
| -85% | -$4.39M | ﹤0.01% | 4315 |
|
|
2019
Q4 | $7.18M | Buy |
589,634
+396,887
| +206% | +$4.34M | ﹤0.01% | 2792 |
|
|
2019
Q3 | $2.23M | Sell |
192,747
-188,820
| -49% | -$1.99M | ﹤0.01% | 3682 |
|
|
2019
Q2 | $3.81M | Buy |
381,567
+356,826
| +1,442% | +$3.85M | ﹤0.01% | 3209 |
|
|
2019
Q1 | $319K | Sell |
24,741
-38,431
| -61% | -$572K | ﹤0.01% | 4814 |
|
|
2018
Q4 | $960K | Sell |
63,172
-39,193
| -38% | -$747K | ﹤0.01% | 4308 |
|
|
2018
Q3 | $2.05M | Sell |
102,365
-1,148
| -1% | -$26.1K | ﹤0.01% | 3979 |
|
|
2018
Q2 | $2.02M | Sell |
103,513
-9,233
| -8% | -$204K | ﹤0.01% | 4072 |
|
|
2018
Q1 | $2.27M | Sell |
112,746
-16,558
| -13% | -$280K | ﹤0.01% | 3887 |
|
|
2017
Q4 | $1.71M | Sell |
129,304
-443,802
| -77% | -$6.69M | ﹤0.01% | 4151 |
|
|
2017
Q3 | $10.6M | Sell |
573,106
-155,907
| -21% | -$2.91M | ﹤0.01% | 2214 |
|
|
2017
Q2 | $13.4M | Sell |
729,013
-279,862
| -28% | -$5.55M | ﹤0.01% | 1887 |
|
|
2017
Q1 | $22.8M | Sell |
1,008,875
-4,038
| -0.4% | -$96.7K | 0.01% | 1446 |
|
|
2016
Q4 | $35.2M | Sell |
1,012,913
-14,760
| -1% | -$441K | 0.01% | 1091 |
|
|
2016
Q3 | $25.2M | Buy |
1,027,673
+52,098
| +5% | +$1.3M | 0.01% | 1289 |
|
|
2016
Q2 | $23.3M | Buy |
975,575
+589,567
| +153% | +$13.5M | 0.01% | 1304 |
|
|
2016
Q1 | $9.03M | Buy |
386,008
+193,210
| +100% | +$4.59M | ﹤0.01% | 1936 |
|
|
2015
Q4 | $5.82M | Sell |
192,798
-309,663
| -62% | -$10M | ﹤0.01% | 2518 |
|
|
2015
Q3 | $20M | Buy |
502,461
+321,130
| +177% | +$19.9M | 0.01% | 1374 |
|
|
2015
Q2 | $12.5M | Buy |
181,331
+56,328
| +45% | +$3.54M | ﹤0.01% | 1890 |
|
|
2015
Q1 | $6.83M | Sell |
125,003
-184,960
| -60% | -$8.82M | ﹤0.01% | 2448 |
|
|
2014
Q4 | $13.2M | Sell |
309,963
-77,011
| -20% | -$2.78M | ﹤0.01% | 1807 |
|
|
2014
Q3 | $12.3M | Sell |
386,974
-257,319
| -40% | -$5.49M | ﹤0.01% | 1840 |
|
|
2014
Q2 | $13.3M | Buy |
644,293
+101,107
| +19% | +$1.87M | 0.01% | 1770 |
|
|
2014
Q1 | $10.5M | Buy |
543,186
+191,216
| +54% | +$4.06M | ﹤0.01% | 1927 |
|
|
2013
Q4 | $8.55M | Buy |
351,970
+149,648
| +74% | +$3.52M | ﹤0.01% | 2077 |
|
|
2013
Q3 | $4.34M | Buy |
+202,322
| New | +$4.78M | ﹤0.01% | 2572 |
|
Morgan Stanley's AMAG Position: Q4 2020 in Review
Morgan Stanley sold out of AMAG Pharmaceuticals (AMAG) in Q4 2020, closing a stake of 605,625 shares — an estimated $5.69M sold.
Morgan Stanley first reported a position in AMAG in Q3 2013 and held it in 29 quarters. The position peaked at $35.2M in Q4 2016. 1 fund tracked by Wall St. Rank holds AMAG as of Q4 2020.
- Morgan Stanley reported no remaining AMAG Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
- Morgan Stanley sold 605,625 AMAG Pharmaceuticals shares in Q4 2020, an estimated $5.69M.
- Morgan Stanley first reported a position in AMAG Pharmaceuticals in Q3 2013 and held it in 29 quarters.
- Morgan Stanley's AMAG Pharmaceuticals position peaked at $35.2M in Q4 2016.
- 1 fund tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2020.
Based on Morgan Stanley's 13F filing for Q4 2020, filed 16 Feb 2021.